Accessibility settings

This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (non-eHealth) (944) Methods and Feasibility Studies (759) Epidemiology (253) Immunology, Allergy, Rheumatology (196) Recruitment of Research Participants (472) Early Results from COVID-19 Studies (459)

Published on in Vol 15 (2026)

This is a member publication of University of Birmingham (Jisc)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/81541, first published .
Alternative text does not exist

Transdermal 17β-Estradiol for the Treatment of COVID-19: Protocol of an Early Terminated Phase 2 Randomized Controlled Trial

Transdermal 17β-Estradiol for the Treatment of COVID-19: Protocol of an Early Terminated Phase 2 Randomized Controlled Trial

Authors of this article:

Adel Ganaw1 Author Orcid Image ;   Kayleigh Griffiths2 Author Orcid Image ;   Moad Ehfeda1 Author Orcid Image ;   Ashraf Elmalik1 Author Orcid Image ;   Manoj Varghese1 Author Orcid Image ;   Muna Al Maslamani1 Author Orcid Image ;   Prem Chandra1 Author Orcid Image ;   Hugh Montgomery3 Author Orcid Image ;   Melanie Madhani2 Author Orcid Image
Article Authors Cited by Tweetations Metrics

Adel Ganaw   1 , MD ;   Kayleigh Griffiths   2 , PHD ;   Moad Ehfeda   1 , MD ;   Ashraf Elmalik   1 , MD ;   Manoj Varghese   1 , MD ;   Muna Al Maslamani   1 , MD ;   Prem Chandra   1 , PHD ;   Hugh Montgomery   3 , OBE, FMedSci, MBBS, BSc, FRCP, MD ;   Melanie Madhani   2 , PhD

1 Hamad Medical Corporation, Doha, Qatar

2 Cardiovascular Department, University of Birmingham, Birmingham, United Kingdom

3 Department of Medicine, University College London, London, United Kingdom

Corresponding Author: